explore -WSS

explore

author：Wikipedia 2025-09-02 08:14:27 - browse：75

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： FDA approves world's first CRISPR

focus

WSS

Spinal cord stimulation reduces pain in amputees, study finds

Arena BioWorks launches in Cambridge to speed drug discovery

Hospital chaplains balance Covid safety with patients’ spiritual needs

Chemotherapy shortages won’t get better under Biden’s latest plan

After sickle

FDA approves world's first CRISPR

leisure time

explore

knowledge

Continuity nursing helped my family in our darkest PICU moments

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Activists slam private health insurers over coverage restrictions

After sickle

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Nonprofit, backed by Microsoft, to certify AI tools in health care

Alkermes shareholders re

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Virginia high school admissions case could be legal follow

In shift, Texas to cover initial consult for Afghan baby's gene therapy

entertainment

Pfizer plans to depart BIO

Chemotherapy shortages won’t get better under Biden’s latest plan

Study suggests new cause of Down syndrome: cells linked to aging

Profiling embryos to choose those with higher IQs is almost a reality

Leukemia patients are helped by Syndax's new type of therapy

Nonprofit, backed by Microsoft, to certify AI tools in health care

focus

hotspot

focus

hotspot